

Nixon v. CVS Health Corporation et al.

U.S. Securities Litigation

Role	BFA was appointed as Co-Lead Counsel for the putative class on December 5, 2024.
Background	This case arises from CVS's misrepresentations regarding its ability to control medical costs and health care utilization patterns in its Health Care Benefits segment.
Court	U.S. District Court for the Southern District of New York
Case Number	24-cv-05303
Status	Pending

BFA was appointed as Co-Lead Counsel for the putative class on December 5, 2024. This case arises from CVS's misrepresentations regarding its ability to control medical costs and health care utilization patterns in its Health Care Benefits segment. During the relevant period, the company represented that its "integrated health care model . . . lowers overall health care costs" and that its "Health Care Benefits segment is expected to continue to benefit from Medicare and Commercial membership growth." In truth, however, CVS concealed the impact that escalating medical cost trends and health care utilization patterns had on the company at the time.

BFA filed the amended complaint on March 4, 2025. Defendants filed a motion to dismiss on May 9, 2025.